Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
The aim of this work was to evaluate the efficacy and safety of botulinum toxin A (BTX-A) treatment in patients with neurogenic detrusor overactivity. PUBMED, EMBASE, and Cochrane Library were identified on 13 May 2017 to identify relevant randomized controlled trials. All data obtained were analyze...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/0886022X.2019.1655448 |
| _version_ | 1819101845268725760 |
|---|---|
| author | Shang-Jun Wu Yu-Qiong Xu Zheng-Yan Gao Zhi-Peng Wang Feng Zhao Lin Liu Sheng Wang |
| author_facet | Shang-Jun Wu Yu-Qiong Xu Zheng-Yan Gao Zhi-Peng Wang Feng Zhao Lin Liu Sheng Wang |
| author_sort | Shang-Jun Wu |
| collection | DOAJ |
| description | The aim of this work was to evaluate the efficacy and safety of botulinum toxin A (BTX-A) treatment in patients with neurogenic detrusor overactivity. PUBMED, EMBASE, and Cochrane Library were identified on 13 May 2017 to identify relevant randomized controlled trials. All data obtained were analyzed using Stata 12.0. Five randomized controlled trials were included in this study. Compared to placebo, the BTX-A groups had significantly fewer urinary incontinence (UI) episodes per day and per week (BTX-A with 300 U for frequency of UI per day at week 2, mean difference (MD): −1.13, 95% confidence interval (CI): −1.89 to −0.37; 200 U; BTX-A with 300 U for frequency of UI per week at week 6, MD: −11.42, 95% CI: −13.91 to −8.93; BTX-A with 200 U for frequency of UI per week at week 6, MD: −10.72, 95% CI: −13.40 to −8.04), increased in maximum cystometric capacity at week 6 (BTX-A with 300 U, MD: 154.88, 95% CI: 133.92–175.84; BTX-A with 200 U, MD: 141.30, 95% CI: 121.28–161.33), decreased maximum detrusor pressure at week 6 (BTX-A with 300 U, MD: −31.72, 95% CI: −37.69 to −25.75; BTX-A with 200 U, MD: −33.47, 95% CI: −39.20 to −27.73). For adverse effects, BTX-A was often associated with more complications and urinary tract infections (BTX-A with 300 U: relative risk (RR):1.42, 95% CI: 1.15–1.76; BTX-A with 200 U: RR: 1.42, 95% CI: 1.11–1.82). This meta-analysis suggests that treatment with BTX-A is effective and safe for neurogenic detrusor overactivity, and recommends using BTX-A with 300 U or with 200 U, as suitable dosage. |
| first_indexed | 2024-12-22T01:25:08Z |
| format | Article |
| id | doaj.art-daf89056fdc042cd9a48544943eca330 |
| institution | Directory Open Access Journal |
| issn | 0886-022X 1525-6049 |
| language | English |
| last_indexed | 2024-12-22T01:25:08Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj.art-daf89056fdc042cd9a48544943eca3302022-12-21T18:43:38ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492019-01-0141193794510.1080/0886022X.2019.16554481655448Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysisShang-Jun Wu0Yu-Qiong Xu1Zheng-Yan Gao2Zhi-Peng Wang3Feng Zhao4Lin Liu5Sheng Wang6Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic UniversityPeking University Shenzhen HospitalThe Sixth People's Hospital of Yancheng CityLinzi District People’s Hospital, Binzhou Medical UniversityLinzi District People’s Hospital, Binzhou Medical UniversityLinzi District People’s Hospital, Binzhou Medical UniversityMedical Intensive Care Unit, PKUCare Luzhong HospitalThe aim of this work was to evaluate the efficacy and safety of botulinum toxin A (BTX-A) treatment in patients with neurogenic detrusor overactivity. PUBMED, EMBASE, and Cochrane Library were identified on 13 May 2017 to identify relevant randomized controlled trials. All data obtained were analyzed using Stata 12.0. Five randomized controlled trials were included in this study. Compared to placebo, the BTX-A groups had significantly fewer urinary incontinence (UI) episodes per day and per week (BTX-A with 300 U for frequency of UI per day at week 2, mean difference (MD): −1.13, 95% confidence interval (CI): −1.89 to −0.37; 200 U; BTX-A with 300 U for frequency of UI per week at week 6, MD: −11.42, 95% CI: −13.91 to −8.93; BTX-A with 200 U for frequency of UI per week at week 6, MD: −10.72, 95% CI: −13.40 to −8.04), increased in maximum cystometric capacity at week 6 (BTX-A with 300 U, MD: 154.88, 95% CI: 133.92–175.84; BTX-A with 200 U, MD: 141.30, 95% CI: 121.28–161.33), decreased maximum detrusor pressure at week 6 (BTX-A with 300 U, MD: −31.72, 95% CI: −37.69 to −25.75; BTX-A with 200 U, MD: −33.47, 95% CI: −39.20 to −27.73). For adverse effects, BTX-A was often associated with more complications and urinary tract infections (BTX-A with 300 U: relative risk (RR):1.42, 95% CI: 1.15–1.76; BTX-A with 200 U: RR: 1.42, 95% CI: 1.11–1.82). This meta-analysis suggests that treatment with BTX-A is effective and safe for neurogenic detrusor overactivity, and recommends using BTX-A with 300 U or with 200 U, as suitable dosage.http://dx.doi.org/10.1080/0886022X.2019.1655448neurogenic detrusor overactivitybotulinum toxin aurinary incontinenceadverse effectsmeta-analysis |
| spellingShingle | Shang-Jun Wu Yu-Qiong Xu Zheng-Yan Gao Zhi-Peng Wang Feng Zhao Lin Liu Sheng Wang Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis Renal Failure neurogenic detrusor overactivity botulinum toxin a urinary incontinence adverse effects meta-analysis |
| title | Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis |
| title_full | Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis |
| title_fullStr | Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis |
| title_full_unstemmed | Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis |
| title_short | Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis |
| title_sort | clinical outcomes of botulinum toxin a management for neurogenic detrusor overactivity meta analysis |
| topic | neurogenic detrusor overactivity botulinum toxin a urinary incontinence adverse effects meta-analysis |
| url | http://dx.doi.org/10.1080/0886022X.2019.1655448 |
| work_keys_str_mv | AT shangjunwu clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis AT yuqiongxu clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis AT zhengyangao clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis AT zhipengwang clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis AT fengzhao clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis AT linliu clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis AT shengwang clinicaloutcomesofbotulinumtoxinamanagementforneurogenicdetrusoroveractivitymetaanalysis |